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Abstract:  
Background: 
Altered hormonal regulation, including cortisol, is a proposed mechanism linking adiposity to 
obesity-related disorders. African Americans (AAs) have differences in body fat distribution 
compared to whites including less visceral and more subcutaneous fat, which may be reflected 
in the association of cortisol with adiposity.  We examined the association of anthropometric, 
adipokine and body fat distribution measures of adiposity with morning serum cortisol (cortisol) 
in an AA cohort, the Jackson Heart Study. 
 
Methods: 
We examined the cross-sectional associations of adiposity measures (body mass index [BMI], 
waist circumference [WC], leptin, adiponectin, leptin:adiponectin ratio [LAR], subcutaneous 
[SAT] and visceral adipose tissue [VAT], and liver fat with cortisol. Leptin, adiponectin, LAR, 
cortisol, SAT, VAT, and liver fat were log-transformed and standardized (z-scores) prior to 
analysis due to positively skewed distributions. Linear regression models were used to analyze 
the association between exposures and cortisol. Models were adjusted for age, sex, education, 
occupation, systolic blood pressure, smoking, physical activity, hormone replacement therapy, 
β-blocker medication, and time of cortisol collection.  
 
Results: 
Among 4,211 participants, a 1-SD higher BMI, WC, leptin, leptin:adiponectin ratio, SAT were 
associated with a 3.92%, 3.05%, 6.48%, 4.97% and 4.97% lower cortisol (all p < 0.001). A 1-SD 
higher adiponectin was associated with a 2.33% higher cortisol (p<0.001). Leptin levels in the 
2nd - 4th quartiles were associated with a graded 7.6%, 11.6%, 15.5% lower cortisol, respectively 
(all p<0.0001). Compared to normal BMI, overweight BMI (25-29.99 kg/m2) and obese BMI (≥ 
 3 
30 kg/m2) were associated with a graded 7.7% and 13.2% lower cortisol, respectively (both 
p<0.0001). There were no associations of liver fat or VAT with cortisol. 
 
Conclusion:  
Several measures of adiposity are associated with lower morning serum cortisol among AAs 
with leptin having the greatest magnitude. Future studies examining the role of morning serum 
cortisol in the pathway from adiposity to cardiometabolic disease in AAs are warranted. 
 
Keywords: Adiposity, Body Mass Index, Body Fat Distribution, Adipokines, Cortisol, African 
Americans 
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INTRODUCTION:  
Obesity impacts nearly 1 in 2 African Americans (AAs) in the United States (US) (1). Visceral 
adipose tissue (VAT) actively secretes pro-inflammatory cytokines and is associated with an 
increased risk of coronary artery disease (2, 3)). Interestingly, AAs have less VAT and more 
subcutaneous adipose tissue (SAT) compared to non-Hispanic whites (NHWs) and other 
racial/ethnic groups (4, 5). Despite having a lower burden of VAT, AAs have a significantly 
higher prevalence of cardiovascular disease (CVD) than NHWs (6). This discrepancy suggests 
that adiposity may drive cardiometabolic disease through factors independent of visceral 
adiposity in AAs. Thus, there is a need to explore novel risk factors that are influenced by 
adiposity and are known to increase CVD risk. One such risk factor is cortisol, whose excess 
and dysregulation with respect to normal circadian patterns is associated with cardiometabolic 
disease and mortality (7, 8).  
Perturbations of the hypothalamic-pituitary-adrenal (HPA) axis and cortisol have been cross-
sectionally associated with obesity (BMI>30 kg/m2) and obesity related conditions including 
insulin resistance, type 2 diabetes, metabolic syndrome and CVD (9, 10). A meta-analysis of 
smaller studies reported mixed associations between adiposity and morning blood cortisol; 
however, larger studies have found significant negative associations between anthropometric 
measures of adiposity and serum/plasma cortisol in Caucasian individuals (11–13). Higher BMIs 
and greater waist circumferences are consistently associated with lower salivary wake-up 
cortisol and cortisol awakening responses (14, 15). Additionally, a U-shaped relationship 
between adiposity and morning serum cortisol has been identified (16). With the exception of 
one study (14), these associations have been investigated in predominantly non-Hispanic white 
and European individuals. Among community dwelling individuals, longitudinal studies suggest 
that changes in adiposity drive perturbation of the HPA axis and cortisol production (17, 18). 
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These studies suggest that temporality favors changes in adiposity preceding alterations in 
systemic cortisol production. 
 
Previous studies have been limited to anthropometric assessments of adiposity (BMI, WC, 
waist-to-hip ratio) and lacked the ability to examine more specific measures of adiposity 
including adipokines and body fat distribution in association with cortisol in large populations. 
Furthermore, previous studies have suffered from a lack of racial/ethnic diversity or power to 
perform race stratified analyses. Given that significant racial/ethnic differences exist in adipose 
tissue distribution (4, 5), we examined the association between measures of adiposity and 
morning serum cortisol in African Americans in the Jackson Heart Study. We hypothesized that 
anthropometric (waist circumference, BMI), adipokines (leptin, leptin: adiponectin ratio [LAR]) 
and body fat distribution (VAT, SAT, Liver Fat) measures of adiposity would be negatively 
associated, while adiponectin would be positively associated with morning serum cortisol.   
 
METHODS:  
Study Population:  
The Jackson Heart Study (JHS) is a prospective cohort study of 5,306 African American adults, 
aged 21-94 from the tri-county area of metropolitan Jackson, Mississippi. The Initial examination 
of participants was performed between 2000-2004 and they were followed-up twice between 
2005-2008 and 2009-2013. The design of the JHS has been described elsewhere (19). The 
study was approved by the institutional review boards of the University of Mississippi Medical 
Center, Jackson State University, and Tougaloo College. All participants provided informed 
consent. Participants were excluded if they had missing data on exposures (morning serum 
cortisol [n=113]), outcomes (adiponectin [n=91], leptin [n=21], waist circumference [n=6], BMI 
[n=1 exam 1], or important covariates at the initial exam (education [n=23], systolic blood 
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pressure [n=15], smoking [n=38], diabetes status [n=4], beta-blockers [n=381]), and cortisol 
measuring time missing or after 12 pm [n=402] (Figure 1).  
Assessment of Adiposity Measures:  
WC was measured at the level of the umbilicus in centimeters (cm) and BMI was calculated as 
weight, in kilograms (kg), divided by height, in meters (m), squared. Visceral and subcutaneous 
adipose tissue volume as well as liver attenuation were measured via multidetector computed 
tomography (CT). The protocol for CT assessment of adiposity in the JHS has been previously 
described (20). Briefly, a 16-channel multidetector CT system equipped with cardiac gating 
(Lightspeed 16 Pro; GE Healthcare, Milwaukee, WI) scanned the heart and lower abdomen. 
Quality control and image analysis were performed at a core reading center (Wake Forest 
University School of Medicine, Winston-Salem, NC). VAT and SAT were assessed from 
abdominal imaging slices covering the lower abdomen from L3 to S1. In total, 24 contiguous 2-
mm-thick slices centered on the lumbar disk space at L4–L5 were used for this analysis; 12 
images before the center of the L4–L5 disk space and 12 images after the disk space were 
used for quantification of VAT and SAT. The abdominal muscular wall was first manually traced, 
and the fat volumes in different compartments were measured by semiautomatic segmentation 
technique. Volume analysis software (Advantage Windows; GE Healthcare, Waukesha, WI) was 
used to segment and characterize each individual voxel as a tissue attenuation of fat using a 
threshold range of −190 to −30 Hounsfield units (HU). The VAT and SAT volumes were the sum 
of VAT and SAT voxels over 24 slices. A CT diagnosis of fat infiltration in the liver was made by 
measurement of liver attenuation (LA) in HU in the right lobe of the liver at the T12-L1 
intervertebral space. As liver fat increases, the measured LA decreases based on the HU in 
which fat has negative values. The LA was determined by calculating the mean Hus of three 
circular regions of interest measuring 100 mm2 in the parenchyma of the right lobe of the liver. 
Given that CT measures were collected at Exam 2, we tested for change in adiposity between 
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Exam 1 and 2 (median 4 years). To determine the variance of adiposity levels in the time 
between Exams 1 and 2, the intraclass correlation coefficients (ICC) were analyzed for BMI, 
WC, and WHR. The ICC for BMI, WC, and WHR was 0.90, 0.83, and 0.83 respectively. The 
intraclass correlations were greater than 80%, suggesting adiposity was consistent between 
visits. Thus, CT measures were included in cross-sectional analyses. 
 
Assessment of Adipokines:  
Leptin and adiponectin were assessed using venous blood which was collected after a minimum 
of 8 hours of fasting and 20 minutes in the supine position. Blood samples were processed 
using a standardized protocol and were stored at -80°C before serum adiponectin and leptin 
was measured (19). Total adiponectin concentration was measured using an ELISA system 
(R&D Systems; Minneapolis, MN, USA). The inter-assay coefficient of variation was 8.8% (21). 
Leptin was measured with a Human Leptin RIA kit (LINCO Research, St. Charles, MI, USA). 
Coefficients of variation was 10% (22). The leptin:adiponectin ratio was calculated via division of 
leptin by adiponectin.  
 
Assessment of Morning Serum Cortisol:  
Normal diurnal cortisol regulation follows a circadian pattern, in which levels are typically high 
upon waking, rise during the first 30–40 minute post-awakening and decline across the day, 
reaching a nadir in the late evening around 11pm-midnight (23). In the JHS, fasting serum 
cortisol was collected in the morning between 8am and 12 pm. Serum cortisol levels were 
measured by chemiluminescent immunoassay performed on an immunoassay system (ADVIA 
Centaur; Siemens). Intra-assay coefficients of variation were 9.1% and 7.7% for high and low 
cortisol concentrations, respectively. 
 
Assessment of Covariates: 
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Information regarding covariates was obtained at the baseline exam. Data were collected during 
visits to the clinic or at home using questionnaires designed to assess occupation 
(management/professional versus not), educational attainment (less than high school versus 
high school diploma/GED equivalent), smoking status (current smoking versus not), medical 
conditions and medication use (beta-blocker/hormone replacement therapy). Systolic blood 
pressure was taken while seated and was measured twice in 5-minute intervals. The average of 
the two measurements was used for the analysis. Physical activity was categorized according to 
the AHA 2020 Cardiovascular health guidelines as poor, intermediate, or ideal, as described 
previously (24).  
 
Statistical Analyses: 
Baseline characteristics of participants were presented and compared across tertiles of BMI 
using analysis of variance (ANOVA) for parametric continuous variables, the Kruskal-Wallis test 
for non-parametric continuous variables, and the chi-square test for categorical variables. Due 
to skewed distributions, cortisol, adiponectin, leptin, LAR, SAT, VAT, and liver fat measures 
were log-transformed prior to the analysis. We used multivariable linear regression models to 
assess the association between anthropometric (BMI & WC), CT (VAT, SAT, & Liver Fat), and 
biomarker (Adiponectin, Leptin, & LAR) measures of adiposity after testing for a non-linear 
association between measures of adiposity and log-morning serum cortisol (Supplementary 
Figure 1).  Relative magnitudes of associations between exposures and morning serum cortisol 
were assessed by standardizing each exposure variable. Various demographic, socioeconomic, 
and biological factors which have previously been shown to be associated with the exposure, 
outcome, or both were controlled for in the model. Both age and male sex are consistently 
associated with higher total daily cortisol output (25, 26). Higher levels of education are 
associated with greater wake up cortisol levels and higher total daily output across the day 
among AAs (27). Higher socioeconomic status, a proxy for both greater occupational and 
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educational attainment, is associated with a lower wake up cortisol (28). Individuals who actively 
smoke have higher total cortisol output throughout the day (29). Systolic blood pressure is well 
known to increase with adiposity and may be a proxy for increased sympathetic nervous system 
activity (30). Beta-blocker medications have significant interactions with the HPA-axis. Estrogen 
monotherapy increases circulating plasma cortisol while an estrogen and progestin combination 
shows a trend towards increasing cortisol (31). Furthermore, HRT influences body composition 
in post-menopausal women (32). Finally, due to the circadian nature of cortisol output, we 
controlled for time of cortisol collection. Effect modification was tested by age and sex by 
inserting multiplicative interaction terms in the models and using the likelihood ratio test. 
Statistical significance was defined as two-sided alpha <0.05 in the main analysis and <0.10 for 
interactions (33). Analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA). 
 
RESULTS: 
Among 4,211 participants, the majority were female (64%), had a level of education equivalent 
to or greater than a high school diploma (81%), were non-smokers (87%), and did not have 
diabetes (79%). The average participant was 54.9 years old (SD: 12.7), had a BMI of 31.7 kg/m2 
(SD: 7.2), and a waist circumference of 100.6 cm (SD: 16.2). Participants in higher tertiles of 
BMI were significantly less likely to smoke, had lower levels of morning serum cortisol, a greater 
prevalence of diabetes, and higher systolic blood pressures. Individuals in higher categories of 
BMI had lower adiponectin and liver attenuation as well as higher leptin, SAT, and VAT (Table 
1). 
 
Examining the continuous relationships between adiposity measures and cortisol (Table 2), a 
1% higher adiponectin was found to be associated with a 0.034% higher morning serum 
cortisol. A 1% higher leptin and LAR were associated with 0.07% and 0.045% lower cortisol, 
respectively, in the fully adjusted models (both p<0.001). A 1 kg/m2 higher BMI and 1 cm higher 
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WC were associated with 0.6% and 0.2% lower cortisol, respectfully (both p<0.0001). A 1% 
higher SAT was associated with a 0.1% lower morning serum cortisol in the fully adjusted model 
(p<0.0001). No associations were observed between visceral adipose tissue and liver 
attenuation with baseline cortisol. 
 
A 1-SD unit increase in leptin was associated with a 6.48% (𝛽= -0.067, CI: -0.084, -0.05, 
p<0.0001) lower morning serum cortisol and a 1-SD higher adiponectin was associated with a 
2.33% (𝛽= 0.023, CI: 0.01, 0.036, p=0.0005) higher morning serum cortisol. Both a 1-SD unit 
increase in LAR and SAT were associated with a 4.97% (LAR [𝛽= -0.051, CI -0.065, -0.038, 
<.0001] & SAT [𝛽= -0.051, CI, -0.07, -0.032, <.0001]) lower morning serum cortisol. A 1-SD 
higher WC and BMI were associated with a 3.05% (𝛽= -0.031, CI: -0.043, -0.018) and 3.92% 
(𝛽= -0.04, CI: -0.052, -0.027) lower morning serum cortisol (both p<0.0001, Table 3, Figure 3).  
 
In the categorical analysis (Table 4), adiponectin in quartile 4 was associated with a 5.7% higher 
cortisol than quartile 1 with no evidence for a graded association. Leptin in the 2nd, 3rd, and 4th 
quartiles was associated with 7.6%, 11.6%, 15.5% lower cortisol (respectively) compared to the 
1st quartile. Increasing quartiles of the LAR and waist circumference were also associated with 
lower morning serum cortisol. Compared to normal BMI, overweight and obese BMI was 
associated with a 7.7% and 13.2% lower cortisol, respectively. SAT in the 3rd and 4th quartiles 
were associated with a 10.1% and 10.0% lower cortisol, respectively (all p<0.05).  No significant 
associations were identified in the fully adjusted models assessing the association of VAT and 
liver attenuation with cortisol. 
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No consistent effect modification was identified by age and sex. Additionally, there was no 
evidence of a U-shaped association between measures of adiposity and morning serum cortisol 
(Supplementary Figure 1a-d). 
 
DISCUSSION:  
In a large sample of AAs, we examined the association of adiposity measures, including 
anthropometric, adipokine and body fat distribution with morning serum cortisol. In this study, 
leptin, LAR, BMI, WC, and SAT were negatively associated while adiponectin was positively 
associated with morning serum cortisol. Leptin had the greatest magnitude of relative 
association with morning serum cortisol in standardized analyses. 
 
Anthropometric Measures 
Previous studies have investigated the cross-sectional relationship between anthropometric 
adiposity measures and cortisol; however, to our knowledge, this is the first to examine these 
associations in a large cohort of AAs and, more generally, with objective measures of adiposity 
including adipokines and CT measures of body fat distribution. Concordant with our study, BMI, 
WC, and hip circumference had significant negative correlations with morning serum cortisol, 
among middle-aged Scandinavian men (11) and middle-aged white men (34). While there was 
no evidence of effect modification by sex in the JHS, differences in the association between 
adiposity and cortisol have previously been identified between men and women in other 
populations. In a larger Scandinavian cohort, fasting cortisol was negatively correlated with 
measures of central adiposity in women, but not in men (13). Similarly, body weight and mean 
24-hour plasma cortisol are inversely correlated among women; however, the two are invariant 
in men (35). The lack of sex specific differences may be related to the high degree of 
generalized and abdominal obesity in the JHS compared to other previous studies and the 
detailed phenotypic biological and imaging characterizations used in this study. 
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Some prior studies are discordant with those aforementioned having identified non-linear 
relationships between obesity and morning serum cortisol among whites.. A U-shaped 
association between BMI and morning serum cortisol has been identified with cortisol nadiring 
at a BMI of 32 among white women (16). However, another study identified a linear association 
of BMI with cortisol (15). In the current study, there was no evidence of a U-shaped association 
between either BMI or WC and morning serum cortisol. This may be due to the distribution of 
BMI in the JHS with only 14% of the participants having a BMI < 25 and mean BMI of 22.7 
kg/m2 among those participants. One potential hypothesis that may explain the previously 
identified U-shaped association is that the state of “underweight” may drive HPA axis activation 
and cortisol output. In the current sample, very few participants had a BMI < 18 kg/m2, which 
may have hindered our ability to detect a significant signal.  
 
Studies examining the association between adiposity and free salivary cortisol show similar 
results to those assessing plasma and serum cortisol. In the Whitehall II cohort, a linear trend 
between increasing categories of BMI (underweight, normal, overweight, and obese) and lower 
wake-up cortisol as well as blunted cortisol awakening responses was reported. These 
associations were mirrored with WC as the exposure (15). While the majority of investigations 
examining these associations were in Caucasian participants, an analysis in the Multi-Ethnic 
Study of Atherosclerosis (MESA) reported similar findings, but were limited in power for 
racial/ethnic stratifications (14). 
 
The hypothesized temporality of the associations between BMI and WC with altered HPA-axis 
function is that adiposity precedes perturbations of the glucocorticoid-regulating system. This 
hypothesis is based on work in MESA where investigators found that a 1% higher annual 
change in BMI was associated with a 2.9% lower wake-up and 3.1% lower 16-hour AUC 
 13 
salivary cortisol over a seven year period (17). Similar associations were reported with waist 
circumference as the exposure. These findings are corroborated by the Massachusetts Male 
Aging Study (18). Although the current study is cross-sectional, it is consistent with these 
previous findings as we found negative cross-sectional associations between continuous 
measures of both BMI and WC with morning serum cortisol.   
 
The specific site of adipose tissue deposition has also been examined as a potential modulating 
factor of morning cortisol levels. In a comparison of abdominally versus peripherally obese 
women, those with abdominal body fat distributions had significantly lower wake-up cortisol and 
cortisol awakening responses than those with peripheral body fat distributions (36). This study, 
however, used less sophisticated measures of adipose tissue distributions than those used in 
the JHS. In the current study, SAT was associated with significantly lower morning serum 
cortisol while VAT and liver fat were unrelated to morning cortisol. Previously, a U-shaped 
relationship between VAT and morning serum cortisol was identified in women (16). Testing for 
a non-linear association between both visceral and liver fat in the JHS revealed no significant 
findings (Supplementary Figure 1c & 1d). VAT and liver fat may be associated to a greater 
degree with local cortisol production, regulated by 11β-hydroxysteroid dehydrogenase type 1 
(11β-HSD1), which may not be reflected in changes to circulating levels.  
 
Body Fat Distribution 
Although, VAT is generally considered a greater component for CVD risk due to its pro-
inflammatory effects, SAT is also cross-sectionally associated with cardiometabolic risk factors 
(37). Given that AAs have the highest rates of obesity in the US, the absolute magnitude of SAT 
may play a larger role in CVD burden than the relative ratio of VAT to SAT. While VAT directly 
secretes IL-6 into circulation, SAT upregulates TNF-α indirectly through leptin production which 
contributes to systemic inflammation (2, 38). In addition to their relationship with systemic 
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inflammation, the current analysis suggests that SAT and leptin are associated with HPA-axis 
dysfunction which may ultimately manifest itself in cardiometabolic disease (Figure 2). As 
previously articulated, lower levels of cortisol in the morning are generally considered indicative 
of HPA-axis dysfunction. Further research is needed to explore cortisol as a potential mediator 
of the relationship between SAT driven adiposity with cardiometabolic disease among AAs.   
 
Adipokines 
To our knowledge, this is the first study to examine the association between leptin and cortisol 
in a large AA cohort. Leptin, is considered the primary peripheral protein involved in appetite 
regulation and exerts its effects largely through the hypothalamus (39). Circulating levels of 
leptin have a strong positive correlation with overall fat mass as it is secreted primarily by 
subcutaneous adipose tissue (40). Interestingly, leptin and cortisol share an inverse circadian 
rhythm which is suggestive of potential counter-regulation (41). In support of this relationship, 
leptin is able to directly suppress the activity of the HPA-axis at the hypothalamus as it blunts 
the release of corticotropin releasing hormone (CRH) in response to hypoglycemic stress (42). 
Additionally, incubation of adrenocortical cells with leptin inhibits both basal and 
adrenocorticotropin hormone (ACTH) stimulated cortisol release, further linking leptin to 
attenuated systemic cortisol production (43, 44). Two previous investigations have examined 
the relationship between leptin as the exposure and cortisol as the outcome. In one study of 11 
healthy young men evaluating the influence of sleep duration on various biomarkers including 
24-hour measures of leptin and cortisol, where researchers found an inverse relationship 
throughout the daytime (41). In the other, leptin did not significantly correlate with cortisol 
among middle-aged Scandinavian men (11). In the current study, the negative association 
between leptin and morning serum cortisol may explain the relationship observed with SAT as 
the exposure. SAT was negatively associated with morning serum cortisol in the continuous 
model. Given the ability of leptin to suppress the activation of the HPA-axis at the hypothalamus 
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and cortisol production at the adrenal gland, the association may be explained through this 
shared molecular physiology.  
 
Adiponectin, the most abundant adipokine in circulation, increases insulin sensitivity, is an anti-
inflammatory protein, and is protective against cardiovascular disease (45). It is exclusively 
produced by adipocytes and decreases as adipocytes expand, thus is inversely correlated with 
BMI, body fat percentage, waist circumference, as well as VAT and SAT (46).  Consistent with 
our findings in a small study of Caucasian men and women, those with adiponectin levels in the 
fourth quartile had significantly higher morning serum cortisol levels than those in lower quartiles 
of adiponectin (47).  
 
To our knowledge, this is also the first investigation to examine the association between the 
LAR and cortisol. The LAR may be a potential surrogate measure estimating adipose tissue 
dysfunction (48). Increasing fat cell size is associated with lower adiponectin expression and is 
secreted to a greater degree by SAT (49–51). Furthermore, leptin is also primarily expressed by 
SAT (40). This suggests that the LAR may have more specificity for SAT dysfunction. 
Interestingly, the standardized LAR and SAT had the same relative magnitude of effect on 
morning serum cortisol. The degree of HPA-axis suppression in the morning may thus be a 
function of the magnitude of subcutaneous adipocyte dysfunction.  
  
Our study has several strengths. First, our study uses data from the JHS, which has a large 
sample of AAs, a population who prior had limited data on the relationship between HPA-axis 
dysfunction and measures of adiposity. Next, we were able to assess tissue specific depots of 
adiposity via CT scans of visceral, subcutaneous, and liver fat. Furthermore, we were able to 
assess levels of important adipokines among study participants, thus, giving a greater insight 
into the role of adiposity on potential biochemical links to the HPA-axis. However, this 
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investigation should be interpreted in the light of some limitations. First, given the cross-
sectional nature of the study, the temporality between the associations cannot be determined. 
Second, we were limited by a single measure of morning serum cortisol, and thus, were unable 
to assess the diurnal cortisol profile and its relation to the exposure. Third, the JHS is a single-
site study, which precludes the results from being generalizable to AAs throughout the US. 
Lastly, though the strength of this study is to allow greater understanding of CVD in AAs, our 
work lays the foundation for future studies to further explore the disparities between AAs and 
other racial groups in adiposity, hormonal and adipokine dysregulation, and CVD.  
 
CONCLUSION: 
In conclusion, this is the first study to examine the association between anthropometric, 
adipokine, and body fat distribution with morning serum cortisol in a large group of AAs. Leptin, 
LAR, BMI, WC, and SAT were negatively associated with morning serum cortisol, while 
adiponectin had a positive association with cortisol. The strongest relative association was 
found between leptin and cortisol. AAs have the highest rates of obesity in the US and 
preferentially store adipose tissue in SAT. Leptin is primarily produced from SAT and is able to 
suppress HPA-axis activity leading to potential long-term dysfunction of the system. Thus, the 
interactions between adiposity, leptin, and cortisol axis warrant further investigation among AAs 
for cardiometabolic disease prevention. 
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Table 1: Demographic Summary by Body Mass Index Categories  
Characteristic Level <25 kg/m2 
(n=596) 
25-30 kg/m2 
(n=1373) 
30+ kg/m2 
(n=2242) 
Total (n=4211) p-value 
Age (years) Mean (SD) 54.5 (14.5) 56.3 (12.6) 54.2 (12.2) 54.9 (12.7) <.0001 
Sex Female 320 (54%) 762 (55%) 1626 (73%) 2708 (64%) <.0001 
 Male 276 (46%) 611 (45%) 616 (27%) 1503 (36%)  
Education < high school  124 (21%) 265 (19%) 432 (19%) 821 (19%) 0.6844 
 high school > 472 (79%) 1108 (81%) 1810 (81%) 3390 (81%)  
Occupation Management/ 
Professional 
207 (35%) 524 (38%) 774 (35%) 1505 (36%) 0.0734 
 other 389 (65%) 849 (62%) 1468 (65%) 2706 (64%)  
Physical Activity  
LS7 Category  
Poor Health 300 (50%) 611 (45%) 1135 (51%) 2046 (49%) <.0001 
 Intermediate 
Health 
183 (31%) 427 (31%) 712 (32%) 1322 (31%)  
 Ideal Health 113 (19%) 335 (24%) 395 (18%) 843 (20%)  
Current Smoking  No 458 (77%) 1198 (87%) 2011 (90%) 3667 (87%) <.0001 
 Yes 138 (23%) 175 (13%) 231 (10%) 544 (13%)  
Systolic blood 
pressure (mmHg) 
Mean (SD) 
(min, max) 
125.7 (17.3) 
(88.1, 188) 
126.5 (16.5) 
(78, 199) 
127.9 (16.1) 
(88.1, 228.4) 
127.2 (16.4) 
(78, 228.4) 
0.0028 
Diastolic Blood 
Pressure (mmHg) 
Mean (SD) 
(min, max) 
75.5 (9) 
(50.1, 
110.7) 
75.6 (8.5) 
(48.5, 110.7) 
76.1 (8.6) 
(36, 112.4) 
75.8 (8.6) 
(36, 112.4) 
0.1849 
Body Mass Index 
(kg/m2) 
Mean (SD) 
(min, max) 
22.7 (1.9) 
(14.6, 24.9) 
27.6 (1.4) 
(25, 29.9) 
36.7 (6.1) 
(30, 75.1) 
31.7 (7.2) 
(14.6, 75.1) 
<.0001 
Waist 
Circumference 
(cm) 
Mean (SD) 
(min, max) 
81.8 (8.1) 
(60, 114) 
92.8 (8.1) 
(32, 134) 
110.4 (14.4) 
(66, 244) 
100.6 (16.2) 
(32, 244) 
<.0001 
Waist-Hip Ratio Mean (SD) 
(min, max) 
0.5 (0) 
(0.4, 0.7) 
0.5 (0) 
(0.2, 0.8) 
0.7 (0.1) 
(0.4, 1.3) 
0.6 (0.1) 
(0.2, 1.3) 
<.0001 
Adiponectin* 
(ng/dL) 
Mean (SD) 
(min, max) 
8.6 (0.7) 
(6.1, 10.9) 
8.4 (0.7) 
(5.9, 11) 
8.3 (0.7) 
(5.9, 10.6) 
8.3 (0.7) 
(5.9, 11) 
<.0001 
Leptin* 
(ng/dL) 
Mean (SD) 
(min, max) 
2 (0.9) 
(-0.1, 3.9) 
2.6 (0.8) 
(0.2, 4.5) 
3.5 (0.7) 
(0.5, 5.9) 
3 (1) 
(-0.1, 5.9) 
<.0001 
SAT (cm3)* Mean (SD) 
(min, max) 
missing=286 
7 (0.6) 
(3.4, 8.1) 
missing=568 
7.4 (0.3) 
(4.8, 8.3) 
missing=1017 
7.9 (0.3) 
(6.2, 8.6) 
missing=1871 
7.6 (0.5) 
(3.4, 8.6) 
<.0001 
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VAT (cm3)* Mean (SD) 
(min, max) 
missing=286 
6.1 (0.6) 
(4.2, 7.3) 
missing=568 
6.5 (0.5) 
(4.4, 7.6) 
missing=1016 
6.8 (0.4) 
(4.5, 7.9) 
missing=1870 
6.6 (0.5) 
(4.2, 7.9) 
<.0001 
Liver Attenuation 
HU* 
Mean (SD) 
(min, max) 
missing=278 
4.1 (0.1) 
(3.1, 4.5) 
missing=557 
4.1 (0.2) 
(1.8, 4.4) 
missing=989 
4 (0.2) 
(2.3, 4.6) 
missing=1824 
4.1 (0.2) 
(1.8, 4.6) 
<.0001 
Morning Serum  
Cortisol* (μg/dL) 
 
Mean (SD) 
(min, max) 
2.3 (0.4) 
(0.6, 3.6) 
2.2 (0.4) 
(-0.9, 3.5) 
2.1 (0.4) 
(-0.9, 3.6) 
2.2 (0.4) 
(-0.9, 3.6) 
<.0001 
HRT Medication No 516 (87%) 1183 (86%) 1876 (84%) 3575 (85%) 0.0598 
 Yes 36 (6%) 141 (10%) 251 (11%) 428 (10%)  
Beta Blocker  
Medication 
No 560 (94%) 1232 (90%) 1991 (89%) 3783 (90%) 0.0010 
 Yes 36 (6%) 141 (10%) 251 (11%) 428 (10%)  
 
*Indicates Logged Value 
Legend: 
LS7 = Life’s Simple Seven; ideal, intermediate, and poor were defined by American Heart 
Association (AHA) “2020” Guidelines; SAT = Subcutaneous Adipose Tissue; VAT = Visceral 
Adipose Tissue; HU = Hounsfield Units; HRT = Hormone Replacement Therapy. 
 
p-values calculated using chi-square (categorical variables), ANOVA (parametric continuous 
variables, and Kruskal-Wallis test (non-parametric continuous variables).  
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Table 2. Association of Continuous Anthropometric, Adipokines and Body Fat Distribution with Cortisol 
Measures of Adiposity Cortisol * (N=4211) 
 Beta (CI), p-value 
Adiponectin (ng/dL)* 0.034 (0.015, 0.053), 0.0005 
Leptin (ng/dL)* -0.07 (-0.088, -0.052), <.0001 
Leptin: Adiponectin Ratio (LAR)* -0.045 (-0.058, -0.033), <.0001 
Waist circumference (cm) -0.002 (-0.003, -0.001), <.0001 
BMI (kg/m2) -0.006 (-0.007, -0.004), <.0001 
Subcutaneous Adipose Tissue (cm3)* (N=2340) -0.1 (-0.14, -0.06), <.0001 
Visceral Adipose Tissue (cm3)* (N=2341) -0.014 (-0.048, 0.02), 0.4271 
Liver attenuation (Hounsfield units)* (n=2387) 0.029 (-0.054, 0.112), 0.4988 
 
*Indicates Logged Value 
1. Unadjusted model  
2. Adjusted for age, sex, education, occupation, systolic blood pressure, smoking, physical 
activity, hormone replacement therapy medications, beta-blocker medications and cortisol 
collect time. 
 
Logged-dependent variable, level-independent: %∆𝑌 = %e! − 1) ∗ 100 
Logged-dependent variable, logged-independent: %∆𝑌 = (1.01" − 1) ∗ 100% 
 
Interpretations: A 1% higher adiponectin is associated with a 0.034% higher morning serum 
cortisol. A 1% higher leptin is associated with 0.07% lower morning serum cortisol. A 1% higher 
leptin: adiponectin ratio is associated with 0.045% lower cortisol. A 1 kg/m2 higher BMI is 
associated with a 0.6% lower cortisol. A 1 cm higher WC is associated with a 0.2% lower 
cortisol. A 1% higher SAT was associated with a 0.1% lower morning serum cortisol.  
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Table 3. Association of Standardized Continuous Anthropometric, Adipokines and Body Fat 
Distribution with Cortisol 
Measures of Adiposity Cortisol (N=4211) 
 Beta (CI)  
z-Log-Adiponectin (ng/dL)  0.023 (0.01, 0.036), 0.0005 
z-Log-Leptin (ng/dL) -0.067 (-0.084, -0.05), <.0001 
z-Log-Leptin:Adiponectin ratio -0.051 (-0.065, -0.038), <.0001 
z-Waist Circumference (cm) -0.031 (-0.043, -0.018), <.0001 
z-Body Mass Index (kg/m2) -0.04 (-0.052, -0.027), <.0001 
z-Log-Subcutaneous Adipose Tissue (cm3) (N=2340) -0.051 (-0.07, -0.032), <.0001 
z-Log-Visceral Adipose Tissue (cm3) (N=2341) -0.007 (-0.024, 0.01), 0.4271 
z-Liver Attenuation (Hounsfield units) (n=2387)  0.006 (-0.011, 0.022), 0.4988 
 
Adjusted for age, sex, education, occupation, systolic blood pressure, smoking, physical activity, 
hormone replacement therapy medications, beta-blocker medications and cortisol collect time. 
 
Logged-dependent variable, level-independent: %∆𝑌 = %e! − 1) ∗ 100 
 
Interpretations: A 1-SD higher adiponectin is associated with a 2.33% higher morning serum 
cortisol. A 1-SD higher leptin is associated with a 6.48% lower morning serum cortisol. A 1-SD 
higher Leptin:Adiponectin ratio is associated with a 4.97% lower morning serum cortisol. A 1-SD 
higher WC is associated with a 3.05% lower morning serum cortisol. A 1-SD higher BMI is 
associated with a 3.92% lower morning serum cortisol. A 1-SD higher SAT is associated with a 
4.97% lower morning serum cortisol.  
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Table 4. Categorical Associations of Anthropometric, Adipokine and Body Fat Distribution with Cortisol 
Measures of Adiposity Categories Cortisol * (n=4211) 
  Beta (CI), p-value 
Adiponectin (ng/dL) Q1 ref 
 Q2 -0.003 ( -0.039, 0.032), 0.8496 
 Q3 0.029 (-0.007, 0.065), 0.1091 
 Q4 0.055 (0.019, 0.092), 0.0031 
Leptin (ng/dL) Q1 ref 
 Q2 -0.079 (-0.118, -0.04), <.0001 
 Q3 -0.123(-0.168, -0.078), <.0001 
 Q4 -0.168 (-0.214, -0.121), <.0001 
Leptin:Adiponectin Ratio Q1 ref 
 Q2 -0.08 (-0.117, -0.046), <.0001 
 Q3 -0.11 (-0.147, -0.073), <.0001 
 Q4 -0.126 (-0.164, -0.088), <.0001 
Waist (cm) Q1 ref 
 Q2 -0.049 (-0.085, -0.014), 0.0109 
 Q3 -0.069 (-0.104, -0.034), <.0001 
 Q4 -0.09 (-0.126, -0.055), <.0001 
BMI (kg/m2) 1: <25 ref 
 2: 25-30 -0.08 (-0.124, -0.045), <.0001 
 3: 30+ -0.141 (-0.179, -0.104), <.0001 
Subcutaneous Adipose Tissue 
(Hounsfield units) (n=2340) Q1 ref 
 Q2 -0.037 (-0.09, 0.012), 0.1346 
 Q3 -0.107 (-0.157, -0.056), <.0001 
 Q4 -0.105 (-0.157, -0.052), 0.0001 
Visceral Adipose Tissue 
(Hounsfield units) (n=2341) Q1 ref 
 Q2 -0.037 (-0.084, 0.010), 0.1252 
 Q3 -0.004(-0.05, 0.043), 0.8642 
 Q4 -0.015 (-0.063, 0.034), 0.5530 
Liver attenuation 
(Hounsfield units) (n=2387) Q1 ref 
 Q2 0.04 (-0.007, 0.086), 0.0933 
 Q3 0.01 (-0.037, 0.056), 0.6848 
 Q4 0.023 (-0.023, 0.07), 0.3227 
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Adjusted for age, sex, education, occupation, systolic blood pressure, smoking, physical activity, hormone 
replacement therapy medications, beta-blocker medications and cortisol collection time. 
 
Interpretations: %∆𝑌 = %e! − 1) ∗ 100 
 
Examples: Adiponectin levels in quartile 4 were associated with a 5.7% higher cortisol than 
quartile 1. Leptin levels in the 2nd, 3rd, and 4th quartiles were associated with 7.6%, 11.6%, 
15.5% lower cortisol (respectively) compared to the 1st quartile. Compared to those with normal 
BMIs, overweight participants (BMI = 25-29.99 kg/m2) and obese participants (BMI ≥ 30 kg/m2) 
had 7.7% and 13.2% lower cortisol levels, respectively. Subcutaneous adipose tissue in the 3rd 
and 4th quartiles had 10.1% and 10.0% lower cortisol, respectively (p<0.05). 
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Figure 1: The Jackson Heart Study Cortisol and Adiposity Cohort  
 
 
Figure Legend 1: 
 
The Jackson Heart Study cohort included 5,306 participants. Individuals were excluded from the 
analysis due to missing data on morning serum cortisol (n=113) or on the basis of missing time 
of cortisol collection/ collection occurring after 12 P.M (n=402). Furthermore, participants were 
excluded if they had missing outcome or covariate date (adiponectin [n=91], leptin [n=21], waist 
circumference [n=6], BMI [n=1], education [n=23], systolic blood pressure [n=15], smoking 
[n=38], diabetes status [n=4], or beta-blockers [n=381].  
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Figure 2. Summary of Associations between Adiposity Measures and Morning Serum Cortisol 
 
 
Figure 2 Legend: 
Body mass index and waist circumference were negatively associated with morning serum 
cortisol. The hypothesized mechanism between increasing adiposity and lower cortisol among 
African Americans involves the preferential storage of adipose tissue in subcutaneous depots. 
Subcutaneous adipose tissue produces leptin which is able to suppress cortisol production at 
the hypothalamus and the adrenal gland.  
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Figure 3. The Relative Magnitude of the Association of Standardized Adiposity Measures with 
Morning Serum Cortisol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Legend: The relative magnitude of associations of standardized adiposity measures with 
morning serum cortisol are shown. Leptin had the greatest relative magnitude of association 
with morning serum cortisol. The data corresponding with the figure is presented in Table 5.  
* p<0.05, ** p<0.01, *** p<0.001 
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Supplementary Figure 1a.     Supplementary Figure 1b.  
 
 
 
Supplementary Figure 1c.                                       Supplementary Figure 1d. 
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Supplementary Figure 1 Legend:  
Supplementary Figure 1a. depicts the fit of the association between log morning serum cortisol 
and waist circumference. Supplementary Figure 1b. depicts the fit of the association between 
log morning serum cortisol and body mass index. Supplementary Figure 1c. depicts the fit of the 
association between log morning serum cortisol and log visceral adipose tissue. Supplementary 
Figure 1d. depicts the fit of the association between log morning serum cortisol and log liver 
attenuation. There was no evidence of a non-linear association between log morning serum 
cortisol and any of the tested measures of adiposity.  
 
 
   
 
 
 
 
